FDA Approves Isembyld, First SMA Treatment To Target Muscle Loss

The short version
- Scholar Rock announced September 11 that the Food and Drug Administration approved Isembyld, also known as apitegromab-mstn.
- The company said shipments would begin in the coming days as its commercial […] The post FDA Approves Isembyld…
The story
A newly approved treatment for spinal muscular atrophy is moving toward U.S. availability, giving eligible children and adults an additional option to address muscle weakness. Scholar Rock announced September 11 that the Food and Drug Administration approved Isembyld, also known as apitegromab-mstn. The company said shipments would begin in the coming days as its commercial […]
The post FDA Approves Isembyld, First SMA Treatment To Target Muscle Loss appeared first on Dallas Express.
Powered by Gab AI
The Story At A Glance
Reading this article now — analysis appears below
💡 AI analysis provides alternative perspectives on current events